Oramed Pharmaceuticals Inc. financial data

Symbol
ORMP on Nasdaq
Location
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.43K % +266%
Return On Equity 27.3 % +1020%
Return On Assets 25.6 % +1128%
Operating Margin -1.01K % +30.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.8M shares -1.26%
Common Stock, Shares, Outstanding 40.8M shares +1.56%
Entity Public Float 131M USD +0.51%
Common Stock, Value, Issued 490K USD +1.24%
Weighted Average Number of Shares Outstanding, Basic 41.8M shares +2.1%
Weighted Average Number of Shares Outstanding, Diluted 42.8M shares +4.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2M USD
Cost of Revenue 1.99M USD
Research and Development Expense 5.85M USD -11.7%
Selling and Marketing Expense -663K USD -243%
General and Administrative Expense 7.17M USD +11.4%
Operating Income (Loss) -13M USD +0.4%
Nonoperating Income (Expense) 68.1M USD +206%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 55.7M USD
Income Tax Expense (Benefit) 11.1M USD +876%
Net Income (Loss) Attributable to Parent 43.8M USD +988%
Earnings Per Share, Basic 1 USD/shares +836%
Earnings Per Share, Diluted 0 USD/shares +800%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.2M USD
Marketable Securities, Current 4.96M USD +667%
Assets, Current 136M USD -4.66%
Other Long-term Investments 7.16M USD
Property, Plant and Equipment, Net 614K USD -14.5%
Operating Lease, Right-of-Use Asset 817K USD +68.1%
Other Assets, Noncurrent 40K USD
Assets 220M USD +33.6%
Accounts Payable, Current 560K USD
Employee-related Liabilities, Current 233K USD
Accrued Liabilities, Current 585K USD
Liabilities, Current 6.12M USD +16%
Contract with Customer, Liability, Noncurrent 2M USD -50%
Deferred Income Tax Liabilities, Net 7.92M USD
Operating Lease, Liability, Noncurrent 589K USD +217%
Other Liabilities, Noncurrent 60K USD -4.76%
Retained Earnings (Accumulated Deficit) -123M USD +26.3%
Stockholders' Equity Attributable to Parent 203M USD +29.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 202M USD +30.1%
Liabilities and Equity 220M USD +33.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.52M USD -138%
Net Cash Provided by (Used in) Financing Activities -19M USD -882%
Net Cash Provided by (Used in) Investing Activities 23.6M USD -21.3%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 40.8M shares +1.56%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 20.1M USD +111%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 52.2M USD +23.9%
Interest Paid, Excluding Capitalized Interest, Operating Activities 571K USD
Deferred Tax Assets, Valuation Allowance 36.1M USD +26.9%
Operating Lease, Liability 860K USD +100%
Depreciation 30K USD -46.4%
Payments to Acquire Property, Plant, and Equipment 3K USD +50%
Lessee, Operating Lease, Liability, to be Paid 880K USD +97.8%
Operating Lease, Liability, Current 271K USD +11.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 162K USD +16.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 295K USD +33.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 20K USD +25%
Lessee, Operating Lease, Liability, to be Paid, Year Three 134K USD +644%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -3.46%
Unrecognized Tax Benefits 11K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 129K USD
Additional Paid in Capital 319M USD +5.99%
Interest Expense 592K USD